Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E. Bauman, Roger B. Cohen, Nabil F. Saba et al.|Cancers|2022Cited by 11